CytoDyn to present updated CLOVER study data at ESMO
CytoDyn said updated data from its Phase 2 CLOVER study will be presented at the ESMO Congress 2026 in Madrid. The study is evaluating leronlimab with trifluridine/tipiracil and bevacizumab in previously treated metastatic colorectal cancer.